Şirket duyuruları · 05.11.20261 dk okuma
Anaheim Bio Launches with €40 Million Series A Financing to Advance ANA-1 for Calcium Pyrophosphate Deposition Disease into the Clinic
Yerel otomatik çeviri · Kaynağın orijinal dili
Özet
Anaheim spun out of Alesta Therapeutics prior to its recent acquisition by BioMarin Financing provided by Droia Ventures, Frazier Life Sciences, RTW, Novartis Venture Fund, RV Invest and Thuja Capital Runway into…